🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)

Found 10 matching trials

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

N/A

To assess the comparative effectiveness of combination Tiotropium and Oloda...

Status

Completed

Location

HealthCore, Inc.

Start Date

2019-11-01

Trial ID

NCT04184297

Treatments Being Tested

Tiotropium and Olodaterol (Tio+Olo)Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

PHASE3

This study will assess whether switching participants who have benefitted f...

Status

Completed

Location

GSK Investigational Site

Start Date

2021-01-26

Trial ID

NCT04718389

Treatments Being Tested

GSK3511294 (Depemokimab)Mepolizumab Benralizumab Placebo Standard of care (SoC)Pre-filled Syringes (PFS)

Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device

N/A

This observational study evaluates whether lung sound analysis with LungPas...

Status

Unknown

Location

Minsk Clinical Phthisiopulmonology Center

Start Date

2021-09-30

Trial ID

NCT05145894

Treatments Being Tested

Lung auscultation with LungPass device (electronic auscultation)

Effectiveness of Triple Therapy in COPD

N/A

To assess the effectiveness of maintenance treatment of Chronic obstructive...

Status

Completed

Location

Clinical Practice Research Datalink

Start Date

2018-11-10

Trial ID

NCT03724877

Treatments Being Tested

Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

PHASE4

It is recognized that eosinophilic airway inflammation is more likely respo...

Status

Unknown

Location

Taipei Veterans General Hospital

Start Date

2014-07

Trial ID

NCT02546349

Treatments Being Tested

fluticasone/salmeterol, tiotropium

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

PHASE1

This is a double-blind, single dose (four inhalations), four-way cross over...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-12-17

Trial ID

NCT01691547

Treatments Being Tested

UMEC /VI UMEC VI FF

A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

This study aims to assess the effect on total systemic exposure and to char...

Status

Completed

Location

Research Site

Start Date

2024-04-29

Trial ID

NCT06297668

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu spacer

Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

The hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary D...

Status

Completed

Location

Daping Hospital

Start Date

2014-06

Trial ID

NCT02147015

Treatments Being Tested

Glucocorticoids Antibiotics Inhaled corticosteroid (ICS)Long-Acting Muscarinic Antagonists(LAMA)Short-acting beta2-agonist (SABA)Physical treatments long-acting beta2-agonist (LABA)

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

PHASE4

The purpose of the study is to evaluate the effect of BGF MDI compared with...

Status

Recruiting

Location

Research Site

Start Date

2025-11-24

Trial ID

NCT07073950

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol Fumarate Placebo Metered dose inhaler

Previous Next